FDA Clears First RAS-Targeting Pill for Advanced Pancreatic Cancer

The Food and Drug Administration on August 26 approved daraxonrasib, sold under the brand name Rasonque, for adults with metastatic pancreatic adenocarcinoma who have already received at least one prior systemic therapy or who can't tolerate combination chemotherapy. The agency moved roughly six and a half months ahead of its standard review deadline, according to a press announcement reviewed directly on the FDA's website.

The drug, made by Revolution Medicines, works by blocking the RAS family of proteins. That's a meaningful target. According to the FDA press announcement, RAS mutations drive tumor growth in more than 90 percent of pancreatic cancer cases, and previous attempts to inhibit those proteins had gone nowhere for decades. This approval is the first time a RAS inhibitor has made it to market for this disease.

The trial numbers that matter for patients are these: in the phase 3 study of 500 adults with previously treated metastatic disease, those who took Rasonque lived a median of 13.2 months, compared with 6.7 months for those who received standard chemotherapy, according to the FDA's announcement and trial data reported by STAT News. That's a meaningful difference in a disease where time is everything.

It's worth being precise about what the study population actually was. These weren't newly diagnosed patients. They were people who had already been through at least one prior treatment. The improvement in a second-line setting is real, but it doesn't tell us yet what this drug does for patients earlier in their course of treatment. Trials in other settings are underway.

Side effects were notable but, per reporting from Yahoo News, generally less severe than what patients experience on chemotherapy. Common ones included rash, diarrhea, mouth sores, nausea, fatigue, vomiting, and abdominal pain.

The approval was not a surprise to the oncology community. When lead investigator Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, presented the trial data at the 2026 ASCO Annual Meeting in May, Newsweek reported the packed auditorium erupted in a standing ovation. That moment doesn't happen often at a medical conference, and it says something about how starved this field has been for progress.

Dr. Andrew Coveler of the Fred Hutch Cancer Center told NPR that this is "one of the most anticipated approvals I can think of," adding plainly: "This medicine is not a cure but a significant improvement."

The disease context makes that improvement land hard. The American Cancer Society estimates roughly 67,000 new pancreatic cancer cases will be diagnosed in the United States this year, and more than 52,000 people will die from it, according to NPR's coverage of the approval. The five-year survival rate sits at 13 percent. Late detection is part of why: pancreatic cancer is often not found until it has already spread.

Before full approval, more than 2,000 patients had enrolled in an expanded-access program that allowed early use of the drug, Reuters reported, as cited by Newsweek. Those patients will now transition to commercial supply through their insurance.

That transition is where the patient-side picture gets complicated. Revolution Medicines set Rasonque's wholesale acquisition cost at $39,800 for a 30-day supply, which works out to roughly $477,000 annually at list price, according to the company's own disclosure. The list price is not what most patients will actually pay. The company said commercially insured patients may qualify for co-pay assistance that could bring out-of-pocket costs to zero, and Medicare Part D patients face a $2,100 annual out-of-pocket cap for covered drugs in 2026. But "may qualify" and "actually receives timely coverage" are two different things, and prior authorization delays are a genuine risk for patients whose remaining time is measured in months, not years.

Oncologists will be able to prescribe Rasonque immediately, and the Pancreatic Cancer Action Network has noted that previously enrolled expanded-access patients will be moved to commercial supply. For anyone navigating coverage right now, the gap between an FDA approval date and an insurer's coverage determination is a real clinical problem, not a paperwork inconvenience.

Sources cited:
- FDA press announcement, August 26, 2026 (https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer)
- STAT News, August 26, 2026 (https://www.statnews.com/2026/08/26/pancreatic-cancer-drug-rasonque-approved/)
- NPR, August 27, 2026 (https://www.npr.org/2026/08/27/g-s1-140410/fda-approves-landmark-pancreatic-cancer-drug)
- Newsweek, August 26, 2026 (https://www.newsweek.com/rasonque-fda-approval-pancreatic-cancer-cost-availability-12371530)
- Pancreatic Cancer Action Network (https://pancan.org/news/fda-approves-rasonque-daraxonrasib/)
- Yahoo Finance / Revolution Medicines disclosure (https://finance.yahoo.com/personal-finance/banking/article/fda-approves-breakthrough-pancreatic-cancer-pill-daraxonrasib-what-will-it-cost-141353695.html)